<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The carrier rates of a genetic marker for arylsulphatase A pseudodeficiency (<z:chebi fb="37" ids="15365">ASA</z:chebi>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>) were determined in three series of patients with vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VaD) or <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD) </plain></SENT>
<SENT sid="1" pm="."><plain>In the first community-based sample, the 1524 + 95A--&gt;G mutation, which is known to be associated with <z:chebi fb="37" ids="15365">ASA</z:chebi>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>, was present in 35% of VaD cases and none of the AD cases </plain></SENT>
<SENT sid="2" pm="."><plain>In a second sample of cases drawn from a <z:hpo ids='HP_0000726'>Dementia</z:hpo> Register, the mutation rates were 18% (VaD) and 16% (AD) </plain></SENT>
<SENT sid="3" pm="."><plain>Brain DNA from a post-mortem sample revealed the <z:chebi fb="37" ids="15365">ASA</z:chebi>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> mutation in 60% of VaD cases and 34% of AD cases </plain></SENT>
<SENT sid="4" pm="."><plain>These rates are higher than previous studies of culturally similar populations and suggest that <z:chebi fb="37" ids="15365">ASA</z:chebi>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> may be a risk factor for <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
</text></document>